Emcure Pharma received a USFDA EIR for its Sanand facility, classified as Voluntary Action Indicated (VAI). The company’s Q1 net profit rose 42%.
Emcure Pharma received a USFDA EIR for its Sanand facility, classified as Voluntary Action Indicated (VAI). The company’s Q1 net profit rose 42%.